These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 22137924

  • 1. Anti-TNF therapy.
    Thalayasingam N, Isaacs JD.
    Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):549-67. PubMed ID: 22137924
    [Abstract] [Full Text] [Related]

  • 2. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].
    Amano K.
    Nihon Naika Gakkai Zasshi; 2011 Oct 10; 100(10):2966-71. PubMed ID: 22175139
    [No Abstract] [Full Text] [Related]

  • 3. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F, Anelli MG, Rinaldi A, Serafino L, Covelli M, Scioscia C, Iannone F, Lapadula G.
    Drug Dev Res; 2014 Nov 10; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [Abstract] [Full Text] [Related]

  • 4. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H, Horiuchi T, Tsukamoto H, Ueda N.
    Cytokine; 2018 Jan 10; 101():56-63. PubMed ID: 27567553
    [Abstract] [Full Text] [Related]

  • 5. [Biological therapies in rheumatology].
    Von Frenckell C, Malaise MG.
    Rev Med Liege; 2009 Jan 10; 64(5-6):293-300. PubMed ID: 19642462
    [Abstract] [Full Text] [Related]

  • 6. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL, Cohen PR.
    Int J Dermatol; 2011 May 10; 50(5):619-25. PubMed ID: 21506984
    [Abstract] [Full Text] [Related]

  • 7. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
    Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M.
    PLoS One; 2012 May 10; 7(1):e30275. PubMed ID: 22272322
    [Abstract] [Full Text] [Related]

  • 8. Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy.
    Bergman M, De G, Ganguli A, Signorovitch J, Bao Y.
    J Med Econ; 2015 Jan 10; 18(1):37-44. PubMed ID: 24841451
    [Abstract] [Full Text] [Related]

  • 9. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-α antagonist therapy: a meta-analysis of randomized control trials.
    Liu Y, Fan W, Chen H, Yu MX.
    Asian Pac J Cancer Prev; 2014 Jan 10; 15(8):3403-10. PubMed ID: 24870729
    [Abstract] [Full Text] [Related]

  • 10. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL, Valesini G.
    BioDrugs; 2014 Apr 10; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [Abstract] [Full Text] [Related]

  • 11. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
    Pasut G.
    BioDrugs; 2014 Apr 10; 28 Suppl 1():S15-23. PubMed ID: 24687235
    [Abstract] [Full Text] [Related]

  • 12. Potential use of TNF-α inhibitors in systemic sclerosis.
    Murdaca G, Spanò F, Contatore M, Guastalla A, Puppo F.
    Immunotherapy; 2014 Apr 10; 6(3):283-9. PubMed ID: 24762073
    [Abstract] [Full Text] [Related]

  • 13. Tumor necrosis factor inhibitors in psoriasis: an update.
    Kerdel FA, Strober BE.
    Semin Cutan Med Surg; 2014 Mar 10; 33(2 Suppl 2):S31-6. PubMed ID: 24979543
    [Abstract] [Full Text] [Related]

  • 14. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.
    JAMA; 2009 Feb 18; 301(7):737-44. PubMed ID: 19224750
    [Abstract] [Full Text] [Related]

  • 15. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
    Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kalstad S, Rødevand E, Mikkelsen K, Lexberg AS, Kvien TK.
    Ann Rheum Dis; 2013 Nov 18; 72(11):1840-4. PubMed ID: 23562987
    [Abstract] [Full Text] [Related]

  • 16. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.
    J Manag Care Pharm; 2013 Oct 18; 19(8):621-30. PubMed ID: 24074008
    [Abstract] [Full Text] [Related]

  • 17. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA, Agudo M.
    Med Clin (Barc); 2010 May 22; 134(15):684-5. PubMed ID: 20176386
    [No Abstract] [Full Text] [Related]

  • 18. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
    Karampetsou MP, Liossis SN, Sfikakis PP.
    QJM; 2010 Dec 22; 103(12):917-28. PubMed ID: 20802008
    [Abstract] [Full Text] [Related]

  • 19. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul 22; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

  • 20. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis].
    Sibilia J.
    Med Sci (Paris); 2009 Dec 22; 25(12):1033-8. PubMed ID: 20035675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.